Antitumor activity of iRGD-modified red blood cell membrane nanoparticles loaded with Juglone and Oxaliplatin against colorectal cancer.

The stability and release of iRGD-modified RBCm nanoparticles loaded with Jug and Oxa (RBCm-(Jug, Oxa)-iRGD-NPs) were evaluated by Dynamic light scattering (DLS) and ultraviolet spectrophotometer, respectively. The current study demonstrated that RBCm-(Jug, Oxa)-iRGD-NPs had a drug-release profile similar to RBCm-(Jug, Oxa)-NPs, but were more stable. Keywords: Juglone; Oxaliplatin; nanoparticles; iRGD; colorectal cancer EN Juglone Oxaliplatin nanoparticles iRGD colorectal cancer 1301 1316 16 01/25/22 20220201 NES 220201 Poor solubility and non-specific biological distribution are critical obstacles for applying Juglone (Jug) into clinical practice. [Extracted from the article]